Wednesday, 21 March 2012

Azelex



azelaic acid

Dosage Form: cream
Azelex®

(azelaic acid cream) 20%

For Dermatologic Use Only

Not for Ophthalmic Use



DESCRIPTION


Azelex® (azelaic acid cream) 20% contains azelaic acid, a naturally occurring saturated dicarboxylic acid.


Structural Formula: HOOC-(CH2)7-COOH


Chemical Name: 1,7-heptanedicarboxylic acid


Empirical Formula: C9H16O4


Molecular Weight: 188.22



Active Ingredient: Each gram of Azelex® contains azelaic acid......... 0.2 gm (20% w/w).



Inactive Ingredients: cetearyl octanoate; glycerin; glyceryl stearate and cetearyl alcohol and cetyl palmitate and cocoglycerides; PEG-5 glyceryl stearate; propylene glycol; and purified water. Benzoic acid is present as a preservative.



CLINICAL PHARMACOLOGY


The exact mechanism of action of azelaic acid is not known. The following in vitro data are available, but their clinical significance is unknown. Azelaic acid has been shown to possess antimicrobial activity against Propionibacterium acnes and Staphylococcus epidermidis. The antimicrobial action may be attributable to inhibition of microbial cellular protein synthesis.


A normalization of keratinization leading to an anticomedonal effect of azelaic acid may also contribute to its clinical activity. Electron microscopic and immunohistochemical evaluation of skin biopsies from human subjects treated with Azelex® Cream demonstrated a reduction in the thickness of the stratum corneum, a reduction in number and size of keratohyalin granules, and a reduction in the amount and distribution of filaggrin (a protein component of keratohyalin) in epidermal layers. This is suggestive of the ability to decrease microcomedo formation.



Pharmacokinetics: Following a single application of Azelex® Cream to human skin in vitro, azelaic acid penetrates into the stratum corneum (approximately 3 to 5% of the applied dose) and other viable skin layers (up to 10% of the dose is found in the epidermis and dermis). Negligible cutaneous metabolism occurs after topical application. Approximately 4% of the topically applied azelaic acid is systemically absorbed. Azelaic acid is mainly excreted unchanged in the urine but undergoes some β-oxidation to shorter chain dicarboxylic acids. The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics.


Azelaic acid is a dietary constituent (whole grain cereals and animal products), and can be formed endogenously from longer-chain dicarboxylic acids, metabolism of oleic acid, and ψ-oxidation of monocarboxylic acids. Endogenous plasma concentration (20 to 80 ng/mL) and daily urinary excretion (4 to 28 mg) of azelaic acid are highly dependent on dietary intake. After topical treatment with Azelex® Cream in humans, plasma concentration and urinary excretion of azelaic acid are not significantly different from baseline levels.



INDICATIONS AND USAGE


Azelex® Cream is indicated for the topical treatment of mild-to-moderate inflammatory acne vulgaris.



CONTRAINDICATIONS


Azelex® Cream is contraindicated in individuals who have shown hypersensitivity to any of its components.



WARNINGS


Azelex® Cream is for dermatologic use only and not for ophthalmic use.


There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexions, these patients should be monitored for early signs of hypopigmentation.



PRECAUTIONS



General:


If sensitivity or severe irritation develop with the use of Azelex® Cream, treatment should be discontinued and appropriate therapy instituted.



Information for patients:


Patients should be told:


  1. To use Azelex® Cream for the full prescribed treatment period.

  2. To avoid the use of occlusive dressings or wrappings.

  3. To keep Azelex® Cream away from the mouth, eyes and other mucous membranes. If it does come in contact with the eyes, they should wash their eyes with large amounts of water and consult a physician if eye irritation persists.

  4. If they have dark complexions, to report abnormal changes in skin color to their physician.

  5. Due in part to the low pH of azelaic acid, temporary skin irritation (pruritus, burning, or stinging) may occur when Azelex® Cream is applied to broken or inflamed skin, usually at the start of treatment. However, this irritation commonly subsides if treatment is continued. If it continues, Azelex® Cream should be applied only once-a-day, or the treatment should be stopped until these effects have subsided. If troublesome irritation persists, use should be discontinued, and patients should consult their physician.


(See ADVERSE REACTIONS.)

Carcinogenesis, mutagenesis, impairment of fertility:


Azelaic acid is a human dietary component of a simple molecular structure that does not suggest carcinogenic potential, and it does not belong to a class of drugs for which there is a concern about carcinogenicity. Therefore, animal studies to evaluate carcinogenic potential with Azelex® Cream were not deemed necessary. In a battery of tests (Ames assay, HGPRT test in Chinese hamster ovary cells, human lymphocyte test, dominant lethal assay in mice), azelaic acid was found to be nonmutagenic. Animal studies have shown no adverse effects on fertility.



Pregnancy:


Teratogenic Effects: Pregnancy Category B.

Embryotoxic effects were observed in Segment I and Segment II oral studies with rats receiving 2500 mg/kg/day of azelaic acid. Similar effects were observed in Segment II studies in rabbits given 150 to 500 mg/kg/day and in monkeys given 500 mg/kg/day. The doses at which these effects were noted were all within toxic dose ranges for the dams. No teratogenic effects were observed. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.



Nursing Mothers:


Equilibrium dialysis was used to assess human milk partitioning in vitro. At an azelaic acid concentration of 25 μg/mL, the milk/plasma distribution coefficient was 0.7 and the milk/buffer distribution was 1.0, indicating that passage of drug into maternal milk may occur. Since less than 4% of a topically applied dose is systemically absorbed, the uptake of azelaic acid into maternal milk is not expected to cause a significant change from baseline azelaic acid levels in the milk. However, caution should be exercised when Azelex® Cream is administered to a nursing mother.



Pediatric Use:


Safety and effectiveness in pediatric patients under 12 years of age have not been established.



Geriatric Use:


Clinical studies of Azelex® Cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.



Adverse Reactions


During U.S. clinical trials with Azelex®Cream, adverse reactions were generally mild and transient in nature. The most common adverse reactions occurring in approximately 1-5% of patients were pruritus, burning, stinging and tingling. Other adverse reactions such as erythema, dryness, rash, peeling, irritation, dermatitis, and contact dermatitis were reported in less than 1% of subjects. There is the potential for experiencing allergic reactions with use of Azelex®Cream.


In patients using azelaic acid formulations, the following additional adverse experiences have been reported rarely: worsening of asthma, vitiligo depigmentation, small depigmented spots, hypertrichosis, reddening (signs of keratosis pilaris), and exacerbation of recurrent herpes labialis.



DOSAGE AND ADMINISTRATION


After the skin is thoroughly washed and patted dry, a thin film of Azelex® Cream should be gently but thoroughly massaged into the affected areas twice daily, in the morning and evening. The hands should be washed following application. The duration of use of Azelex® Cream can vary from person to person and depends on the severity of the acne. Improvement of the condition occurs in the majority of patients with inflammatory lesions within four weeks.



HOW SUPPLIED


Azelex® Cream is supplied in a closed orifice tube with a white, spiked screwcap in the following sizes:


30 g - NDC 0023-8694-30

50 g - NDC 0023-8694-50


Note: Protect from freezing. Store product on its side.


Store between 15° - 30° C (59° - 86° F).


Rx Only.


Distributed by:



Irvine, California 92612, U.S.A.


©2004 Allergan, Inc.


Made in Italy


8466X


Distributed under license.


® Mark of Allergan, Inc.


Revised May 2004


70896US15P



NDC 0023-8694-50


ALLERGAN®


Azelex®


(azelaic acid cream) 20%


For Dermatologic Use Only


Not for Ophthalmic Use


Rx Only          50 grams




NDC 0023-8694-50


ALLERGAN®


Azelex®


(azelaic acid cream) 20%


For Dermatologic Use Only


Not for Ophthalmic Use          50 grams


Rx Only










Azelex 
azelaic acid  cream










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0023-8694
Route of AdministrationCUTANEOUSDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
azelaic acid (azelaic acid)azelaic acid0.2 g  in 1 g
























Inactive Ingredients
Ingredient NameStrength
cetearyl ethylhexanoate 
glycerin 
cetostearyl alcohol 
cetyl palmitate 
propylene glycol 
water 
glyceryl monostearate 
coco-glycerides 
glyceryl monostearate 
benzoic acid 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      






















Packaging
#NDCPackage DescriptionMultilevel Packaging
10023-8694-301 TUBE In 1 CARTONcontains a TUBE
130 g In 1 TUBEThis package is contained within the CARTON (0023-8694-30)
20023-8694-501 TUBE In 1 CARTONcontains a TUBE
250 g In 1 TUBEThis package is contained within the CARTON (0023-8694-50)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA02042803/21/1996


Labeler - Allergan, Inc. (144796497)









Establishment
NameAddressID/FEIOperations
Intendis Manufacturing SPA564725468MANUFACTURE
Revised: 01/2011Allergan, Inc.

More Azelex resources


  • Azelex Side Effects (in more detail)
  • Azelex Dosage
  • Azelex Use in Pregnancy & Breastfeeding
  • Azelex Drug Interactions
  • Azelex Support Group
  • 2 Reviews for Azelex - Add your own review/rating


  • Azelex Cream MedFacts Consumer Leaflet (Wolters Kluwer)

  • Azelex Topical Advanced Consumer (Micromedex) - Includes Dosage Information

  • Finacea Gel MedFacts Consumer Leaflet (Wolters Kluwer)

  • Finacea Consumer Overview

  • Finacea Plus Gel MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Azelex with other medications


  • Acne
  • Rosacea

Tuesday, 20 March 2012

Protopic 0.03% ointment (Astellas Pharma Ltd)





1. Name Of The Medicinal Product



Protopic 0.03% ointment


2. Qualitative And Quantitative Composition



1 g of Protopic 0.03% ointment contains 0.3 mg of tacrolimus as tacrolimus monohydrate (0.03%).



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Ointment



A white to slightly yellowish ointment.



4. Clinical Particulars



4.1 Therapeutic Indications



Protopic 0.03% ointment is indicated in adults, adolescents and children from the age of 2 years.



Flare treatment



Adults and adolescents (16 years of age and above)



Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids.



Children (2 years of age and above)



Treatment of moderate to severe atopic dermatitis in children who failed to respond adequately to conventional therapies such as topical corticosteroids.



Maintenance treatment



Treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).



4.2 Posology And Method Of Administration



Protopic treatment should be initiated by physicians with experience in the diagnosis and treatment of atopic dermatitis.



Protopic is available in two strengths, Protopic 0.03% and Protopic 0.1% ointment.



Posology



Flare treatment



Protopic can be used for short-term and intermittent long-term treatment. Treatment should not be continuous on a long-term basis.



Protopic treatment should begin at the first appearance of signs and symptoms. Each affected region of the skin should be treated with Protopic until lesions are cleared, almost cleared or mildly affected. Thereafter, patients are considered suitable for maintenance treatment (see below). At the first signs of recurrence (flares) of the disease symptoms, treatment should be re-initiated.



Adults and adolescents (16 years of age and above)



Treatment should be started with Protopic 0.1% twice a day and treatment should be continued until clearance of the lesion. If symptoms recur, twice daily treatment with Protopic 0.1% should be restarted. An attempt should be made to reduce the frequency of application or to use the lower strength Protopic 0.03% ointment if the clinical condition allows.



Generally, improvement is seen within one week of starting treatment. If no signs of improvement are seen after two weeks of treatment, further treatment options should be considered.



Elderly patients



Specific studies have not been conducted in elderly patients. However, the clinical experience available in this patient population has not shown the necessity for any dosage adjustment.



Paediatric population



Children (2 years of age and above) should use the lower strength Protopic 0.03% ointment.



Treatment should be started twice a day for up to three weeks. Afterwards the frequency of application should be reduced to once a day until clearance of the lesion (see section 4.4).



Protopic ointment should not be used in children aged below 2 years until further data are available.



Maintenance treatment



Patients who are responding to up to 6 weeks treatment using tacrolimus ointment twice daily (lesions cleared, almost cleared or mildly affected) are suitable for maintenance treatment.



Adults and adolescents (16 years of age and above)



Adult patients should use Protopic 0.1% ointment.



Protopic ointment should be applied once a day twice weekly (e.g. Monday and Thursday) to areas commonly affected by atopic dermatitis to prevent progression to flares. Between applications there should be 2–3 days without Protopic treatment.



After 12 months treatment, a review of the patient`s condition should be conducted by the physician and a decision taken whether to continue maintenance treatment in the absence of safety data for maintenance treatment beyond 12 months.



If signs of a flare reoccur, twice daily treatment should be re-initiated (see flare treatment section above).



Elderly patients



Specific studies have not been conducted in elderly patients (see flare treatment section above).



Paediatric population



Children (2 years of age and above) should use the lower strength Protopic 0.03% ointment.



Protopic ointment should be applied once a day twice weekly (e.g. Monday and Thursday) to areas commonly affected by atopic dermatitis to prevent progression to flares. Between applications there should be 2–3 days without Protopic treatment.



The review of the child`s condition after 12 months treatment should include suspension of treatment to assess the need to continue this regimen and to evaluate the course of the disease.



Protopic ointment should not be used in children aged below 2 years until further data are available.



Method of administration



Protopic ointment should be applied as a thin layer to affected or commonly affected areas of the skin. Protopic ointment may be used on any part of the body, including face, neck and flexure areas, except on mucous membranes. Protopic ointment should not be applied under occlusion because this method of administration has not been studied in patients (see section 4.4).



4.3 Contraindications



Hypersensitivity to the active substance, macrolides in general, or to any of the excipients.



4.4 Special Warnings And Precautions For Use



Protopic should not be used in patients with congenital or acquired immunodeficiencies or in patients on therapy that cause immunosuppression.



The effect of treatment with Protopic ointment on the developing immune system of children aged below 2 years has not been established (see section 4.1).



Exposure of the skin to sunlight should be minimised and the use of ultraviolet (UV) light from a solarium, therapy with UVB or UVA in combination with psoralens (PUVA) should be avoided during use of Protopic ointment (see section 5.3). Physicians should advise patients on appropriate sun protection methods, such as minimisation of the time in the sun, use of a sunscreen product and covering of the skin with appropriate clothing. Protopic ointment should not be applied to lesions that are considered to be potentially malignant or pre-malignant.



Emollients should not be applied to the same area within 2 hours of applying Protopic ointment. Concomitant use of other topical preparations has not been assessed. There is no experience with concomitant use of systemic steroids or immunosuppressive agents.



Protopic ointment has not been evaluated for its efficacy and safety in the treatment of clinically infected atopic dermatitis. Before commencing treatment with Protopic ointment, clinical infections at treatment sites should be cleared. Patients with atopic dermatitis are predisposed to superficial skin infections. Treatment with Protopic may be associated with an increased risk of folliculitis and herpes viral infections (herpes simplex dermatitis [eczema herpeticum], herpes simplex [cold sores], Kaposi's varicelliform eruption) (see section 4.8). In the presence of these infections, the balance of risks and benefits associated with Protopic use should be evaluated.



The potential for local immunosuppression (possibly resulting in infections or cutaneous malignancies) in the long term (i.e. over a period of years) is unknown (see section 5.1).



Protopic contains the active substance tacrolimus, a calcineurin inhibitor. In transplant patients, prolonged systemic exposure to intense immunosuppression following systemic administration of calcineurin inhibitors has been associated with an increased risk of developing lymphomas and skin malignancies. In patients using tacrolimus ointment, cases of malignancies, including cutaneous and other types of lymphoma, and skin cancers have been reported (see section 4.8). Patients with atopic dermatitis treated with Protopic have not been found to have significant systemic tacrolimus levels.



Lymphadenopathy was uncommonly (0.8%) reported in clinical trials. The majority of these cases were related to infections (skin, respiratory tract, tooth) and resolved with appropriate antibiotic therapy. Transplant patients receiving immunosuppressive regimens (e.g. systemic tacrolimus) are at increased risk for developing lymphoma; therefore patients who receive Protopic and who develop lymphadenopathy should be monitored to ensure that the lymphadenopathy resolves. Lymphadenopathy present at initiation of therapy should be investigated and kept under review. In case of persistent lymphadenopathy, the aetiology of the lymphadenopathy should be investigated. In the absence of a clear aetiology for the lymphadenopathy or in the presence of acute infectious mononucleosis, discontinuation of Protopic should be considered.



Care should be taken to avoid contact with eyes and mucous membranes. If accidentally applied to these areas, the ointment should be thoroughly wiped off and/or rinsed off with water.



The use of Protopic ointment under occlusion has not been studied in patients. Occlusive dressings are not recommended.



As with any topical medicinal product, patients should wash their hands after application if the hands are not intended for treatment.



Tacrolimus is extensively metabolised in the liver and although blood concentrations are low following topical therapy, the ointment should be used with caution in patients with hepatic failure (see section 5.2).



The use of tacrolimus ointment is not recommended in patients with a skin barrier defect, such as Netherton's syndrome, lamellar ichthyosis, generalized erythroderma or cutaneous Graft Versus Host Disease. These skin conditions may increase systemic absorption of tacrolimus. Oral use of tacrolimus is also not recommended to treat these skin conditions. Post-marketing cases of increased tacrolimus blood level have been reported in these conditions.



Care should be exercised if applying Protopic to patients with extensive skin involvement over an extended period of time, especially in children (see section 4.2).



The development of any new change different from previous eczema within a treated area should be reviewed by the physician.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Formal topical drug interaction studies with tacrolimus ointment have not been conducted.



Tacrolimus is not metabolised in human skin, indicating that there is no potential for percutaneous interactions that could affect the metabolism of tacrolimus.



Systemically available tacrolimus is metabolised via the hepatic Cytochrome P450 3A4 (CYP3A4). Systemic exposure from topical application of tacrolimus ointment is low (<1.0 ng/ml) and is unlikely to be affected by concomitant use of substances known to be inhibitors of CYP3A4. However, the possibility of interactions cannot be ruled out and the concomitant systemic administration of known CYP3A4 inhibitors (e.g. erythromycin, itraconazole, ketoconazole and diltiazem) in patients with widespread and/or erythrodermic disease should be done with caution.



Paediatric population



An interaction study with protein-conjugated vaccine against Neisseria menigitidis serogroup C has been investigated in children aged 2-11 years. No effect on immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity has been observed (see section 5.1).



4.6 Pregnancy And Lactation



Fertility



There are no fertility data available.



Pregnancy



There are no adequate data from the use of tacrolimus ointment in pregnant women. Studies in animals have shown reproductive toxicity following systemic administration (see section 5.3). The potential risk for humans is unknown.



Protopic ointment should not be used during pregnancy unless clearly necessary.



Breastfeeding



Human data demonstrate that, after systemic administration, tacrolimus is excreted into breast milk. Although clinical data have shown that systemic exposure from application of tacrolimus ointment is low, breast-feeding during treatment with Protopic ointment is not recommended.



4.7 Effects On Ability To Drive And Use Machines



Protopic ointment is administered topically and is unlikely to have an effect on the ability to drive or use machines.



4.8 Undesirable Effects



In clinical studies approximately 50% of patients experienced some type of skin irritation adverse reaction at the site of application. Burning sensation and pruritus were very common, usually mild to moderate in severity and tended to resolve within one week of starting treatment. Erythema was a common skin irritation adverse reaction. Sensation of warmth, pain, paraesthesia and rash at the site of application were also commonly observed. Alcohol intolerance (facial flushing or skin irritation after consumption of an alcoholic beverage) was common.



Patients may be at an increased risk of folliculitis, acne and herpes viral infections.



Adverse reactions with suspected relationship to treatment are listed below by system organ class. Frequencies are defined as very common ( 1/10), common ( 1/100 to < 1/10) and uncommon (







































System Organ Class




Very Common






Common



<1/10




Uncommon



<1/100




Not known (cannot be estimated from the available data)




Infections and infestations



 


Local skin infection regardless of specific aetiology including but not limited to:



Eczema herpeticum,



Folliculitis,



Herpes simplex,



Herpes virus infection,



Kaposi's varicelliform eruption*



 

 


Metabolism and nutrition disorders



 


Alcohol intolerance (facial flushing or skin irritation after consumption of an alcoholic beverage)



 

 


Nervous system disorders



 


Paraesthesias and dysaesthesias (hyperaesthesia, burning sensation)



 

 


Skin and subcutaneous tissue disorders



 


Pruritus




Acne*




Rosacea*




General disorders and administration site conditions




Application site burning,



Application site pruritus




Application site warmth,



Application site erythema,



Application site pain,



Application site irritation,



Application site paraesthesia,



Application site rash



 


Application site oedema*




Investigations



 

 

 


Drug level increased* (see section 4.4)



* The adverse reaction has been reported during post-marketing experience



Maintenance treatment



In a study of maintenance treatment (twice weekly treatment) in adults and children with moderate and severe atopic dermatitis the following adverse events were noted to occur more frequently than in the control group: application site impetigo (7.7% in children) and application site infections (6.4% in children and 6.3% in adults).



Post-marketing



Cases of malignancies, including cutaneous and other types of lymphoma, and skin cancers, have been reported in patients using tacrolimus ointment (see section 4.4).



Paediatric population



Frequency, type and severity of adverse reactions in children are similar to those reported in adults.



4.9 Overdose



Overdosage following topical administration is unlikely.



If ingested, general supportive measures may be appropriate. These may include monitoring of vital signs and observation of clinical status. Due to the nature of the ointment vehicle, induction of vomiting or gastric lavage is not recommended.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Other dermatologicals, ATC code: D11AH01



Mechanism of action and pharmacodynamic effects



The mechanism of action of tacrolimus in atopic dermatitis is not fully understood. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known.



Via its binding to a specific cytoplasmic immunophilin (FKBP12), tacrolimus inhibits calcium-dependent signal transduction pathways in T cells, thereby preventing the transcription and synthesis of IL-2, IL-3, IL-4, IL-5 and other cytokines such as GM-CSF, TNF-α and IFN-γ.



In vitro, in Langerhans cells isolated from normal human skin, tacrolimus reduced the stimulatory activity towards T cells. Tacrolimus has also been shown to inhibit the release of inflammatory mediators from skin mast cells, basophils and eosinophils.



In animals, tacrolimus ointment suppressed inflammatory reactions in experimental and spontaneous dermatitis models that resemble human atopic dermatitis. Tacrolimus ointment did not reduce skin thickness and did not cause skin atrophy in animals.



In patients with atopic dermatitis, improvement of skin lesions during treatment with tacrolimus ointment was associated with reduced Fc receptor expression on Langerhans cells and a reduction of their hyperstimulatory activity towards T cells. Tacrolimus ointment does not affect collagen synthesis in humans.



Clinical efficacy and safety



The efficacy and safety of Protopic was assessed in more than 18,500 patients treated with tacrolimus ointment in Phase I to Phase III clinical trials. Data from six major trials are presented here.



In a six-month multicentre double-blind randomised trial, 0.1% tacrolimus ointment was administered twice-a-day to adults with moderate to severe atopic dermatitis and compared to a topical corticosteroid based regimen (0.1% hydrocortisone butyrate on trunk and extremities, 1% hydrocortisone acetate on face and neck). The primary endpoint was the response rate at month 3 defined as the proportion of patients with at least 60% improvement in the mEASI (modified Eczema Area and Severity Index) between baseline and month 3. The response rate in the 0.1% tacrolimus group (71.6%) was significantly higher than that in the topical corticosteroid based treatment group (50.8%; p<0.001; Table 1). The response rates at month 6 were comparable to the 3-month results.



Table 1 Efficacy at month 3












 


Topical corticosteroid regimen§



(N=485)




Tacrolimus 0.1%



(N=487)




Response rate of




50.8%




71.6%




Improvement




28.5%




47.7%



§ Topical corticosteroid regimen = 0.1% hydrocortisone butyrate on trunk and extremities, 1% hydrocortisone acetate on face and neck



§§ higher values = greater improvement



The incidence and nature of most adverse events were similar in the two treatment groups. Skin burning, herpes simplex, alcohol intolerance (facial flushing or skin sensitivity after alcohol intake), skin tingling, hyperaesthesia, acne and fungal dermatitis occurred more often in the tacrolimus treatment group. There were no clinically relevant changes in the laboratory values or vital signs in either treatment group throughout the study.



In the second trial, children aged from 2 to 15 years with moderate to severe atopic dermatitis received twice daily treatment for three weeks of 0.03% tacrolimus ointment, 0.1% tacrolimus ointment or 1% hydrocortisone acetate ointment. The primary endpoint was the area-under-the-curve (AUC) of the mEASI as a percentage of baseline averaged over the treatment period. The results of this multicentre, double-blind, randomised trial showed that tacrolimus ointment, 0.03% and 0.1%, is significantly more effective (p<0.001 for both) than 1% hydrocortisone acetate ointment (Table 2).



Table 2 Efficacy at week 3















 


Hydrocortisone acetate 1%



(N=185)




Tacrolimus 0.03%



(N=189)




Tacrolimus 0.1%



(N=186)




Median mEASI as Percentage of Baseline mean AUC (Primary Endpoint)§




64.0%




44.8%




39.8%




Improvement




15.7%




38.5%




48.4%



§ lower values = greater improvement



The incidence of local skin burning was higher in the tacrolimus treatment groups than in the hydrocortisone group. Pruritus decreased over time in the tacrolimus groups but not in the hydrocortisone group. There were no clinically relevant changes in the laboratory values or vital signs in either treatment group throughout the clinical trial.



The purpose of the third multicentre, double-blind, randomised study was the assessment of efficacy and safety of 0.03% tacrolimus ointment applied once or twice a day relative to twice daily administration of 1% hydrocortisone acetate ointment in children with moderate to severe atopic dermatitis. Treatment duration was for up to three weeks.



Table 3 Efficacy at week 3















 


Hydrocortisone acetate 1%



Twice daily (N=207)




Tacrolimus 0.03%



Once daily (N=207)




Tacrolimus 0.03%



Twice daily (N=210)




Median mEASI Percentage Decrease (Primary Endpoint)§




47.2%




70.0%




78.7%




Improvement




13.6%




27.8%




36.7%



§ higher values = greater improvement



The primary endpoint was defined as the percentage decrease in mEASI from the baseline to end of treatment. A statistically significant better improvement was shown for once daily and twice daily 0.03% tacrolimus ointment compared to twice daily hydrocortisone acetate ointment (p<0.001 for both). Twice daily treatment with 0.03% tacrolimus ointment was more effective than once daily administration (Table 3). The incidence of local skin burning was higher in the tacrolimus treatment groups than in the hydrocortisone group. There were no clinically relevant changes in the laboratory values or vital signs in either treatment group throughout the study.



In the fourth trial, approximately 800 patients (aged



The efficacy and safety of tacrolimus ointment in maintenance treatment of mild to severe atopic dermatitis was assessed in 524 patients in two Phase III multicentre clinical trials of similar design, one in adult patients (



The primary endpoint in both studies was the number of disease exacerbations requiring a “substantial therapeutic intervention” during the DCP, defined as an exacerbation with an IGA of 3-5 (i.e. moderate, severe and very severe disease) on the first day of the flare, and requiring more than 7 days treatment. Both studies showed significant benefit with twice weekly treatment with tacrolimus ointment with regard to the primary and key secondary endpoints over a period of 12 months in a pooled population of patients with mild to severe atopic dermatitis. In a subanalysis of a pooled population of patients with moderate to severe atopic dermatitis these differences remained statistically significant (Table 4). No adverse events not reported previously were observed in these studies.



Table 4 Efficacy (moderate to severe subpopulation)






































 


Adults,




Children, 2-15 years


  


Tacrolimus 0.1%



Twice weekly



(N=80)




Vehicle



Twice weekly



(N=73)




Tacrolimus 0.03%



Twice weekly



(N=78)




Vehicle



Twice weekly



(N=75)


 


Median number of DEs requiring substantial intervention adjusted for time at risk (% of patients without DE requiring substantial intervention)




1.0 (48.8%)




5.3 (17.8%)




1.0 (46.2%)




2.9 (21.3%)




Median time to first DE requiring substantial intervention




142 days




15 days




217 days




36 days




Median number of DEs adjusted for time at risk (% of patients without any DE periods)




1.0 (42.5%)




6.8 (12.3%)




1.5 (41.0%)




3.5 (14.7%)




Median time to first DE




123 days




14 days




146 days




17 days




Mean (SD) percentage of days of DE exacerbation treatment




16.1 (23.6)




39.0 (27.8)




16.9 (22.1)




29.9 (26.8)



DE: disease exacerbation



P<0.001 in favour of tacrolimus ointment 0.1% (adults) and 0.03% (children) for the primary and key secondary endpoints



A seven-month, double blind, randomised parallel group study of paediatric patients (2-11 years) with moderate to severe atopic dermatitis was performed. In one arm patients received Protopic 0.03% ointment (n=121) twice a day for 3 weeks and thereafter once a day until clearance. In the comparator arm patients received 1% hydrocortisone acetate ointment (HA) for head and neck and 0.1% hydrocortisone butyrate ointment for trunk and limbs (n=111) twice a day for 2 weeks and subsequently HA twice a day to all affected areas. During this period all patients and control subjects (n=44) received a primary immunisation and a rechallenge with a protein-conjugate vaccine against Neisseria menigitidis serogroup C.



The primary endpoint of this study was the response rate to vaccination, defined as the percentage of patients with a serum bactericidal antibody (SBA) titre



The primary response to vaccination was not affected.



5.2 Pharmacokinetic Properties



Clinical data have shown that tacrolimus concentrations in systemic circulation after topical administration are low and, when measurable, transient.



Absorption



Data from healthy human subjects indicate that there is little or no systemic exposure to tacrolimus following single or repeated topical application of tacrolimus ointment.



Most atopic dermatitis patients (adults and children) treated with single or repeated application of tacrolimus ointment (0.03-0.1%), and infants from age of 5 months treated with tacrolimus ointment (0.03%) had blood concentrations < 1.0 ng/ml. When observed, blood concentrations exceeding 1.0 ng/ml were transient. Systemic exposure increases with increasing treatment areas. However, both the extent and the rate of topical absorption of tacrolimus decrease as the skin heals. In both adults and children with an average of 50% body surface area treated, systemic exposure (i.e. AUC) of tacrolimus from Protopic is approximately 30-fold less than that seen with oral immunosuppressive doses in kidney and liver transplant patients. The lowest tacrolimus blood concentration at which systemic effects can be observed is not known.



There was no evidence of systemic accumulation of tacrolimus in patients (adults and children) treated for prolonged periods (up to one year) with tacrolimus ointment.



Distribution



As systemic exposure is low with tacrolimus ointment, the high binding of tacrolimus (> 98.8%) to plasma proteins is considered not to be clinically relevant.



Following topical application of tacrolimus ointment, tacrolimus is selectively delivered to the skin with minimal diffusion into the systemic circulation.



Metabolism



Metabolism of tacrolimus by human skin was not detectable. Systemically available tacrolimus is extensively metabolised in the liver via CYP3A4.



Elimination



When administered intravenously, tacrolimus has been shown to have a low clearance rate. The average total body clearance is approximately 2.25 l/h. The hepatic clearance of systemically available tacrolimus could be reduced in subjects with severe hepatic impairment, or in subjects who are co-treated with drugs that are potent inhibitors of CYP3A4.



Following repeated topical application of the ointment the average half-life of tacrolimus was estimated to be 75 hours for adults and 65 hours for children.



Paediatric population



The pharmacokinetics of tacrolimus after topical application are similar to those reported in adults, with minimal systemic exposure and no evidence of accumulation (see above).



5.3 Preclinical Safety Data



Repeated dose toxicity and local tolerance



Repeated topical administration of tacrolimus ointment or the ointment vehicle to rats, rabbits and micropigs was associated with slight dermal changes such as erythema, oedema and papules.



Long-term topical treatment of rats with tacrolimus led to systemic toxicity including alterations of kidneys, pancreas, eyes and nervous system. The changes were caused by high systemic exposure of rodents resulting from high transdermal absorption of tacrolimus. Slightly lower body weight gain in females was the only systemic change observed in micropigs at high ointment concentrations (3%).



Rabbits were shown to be especially sensitive to intravenous administration of tacrolimus, reversible cardiotoxic effects being observed.



Mutagenicity



In vitro and in vivo tests did not indicate a genotoxic potential of tacrolimus.



Carcinogenicity



Systemic carcinogenicity studies in mice (18 months) and rats (24 months) revealed no carcinogenic potential of tacrolimus.



In a 24-month dermal carcinogenicity study performed in mice with 0.1% ointment, no skin tumours were observed. In the same study an increased incidence of lymphoma was detected in association with high systemic exposure.



In a photocarcinogenicity study, albino hairless mice were chronically treated with tacrolimus ointment and UV radiation. Animals treated with tacrolimus ointment showed a statistically significant reduction in time to skin tumour (squamous cell carcinoma) development and an increase in the number of tumours. It is unclear whether the effect of tacrolimus is due to systemic immunosuppression or a local effect. The risk for humans cannot be completely ruled out as the potential for local immunosuppression with the long-term use of tacrolimus ointment is unknown.



Reproduction toxicity



Embryo/foetal toxicity was observed in rats and rabbits, but only at doses that caused significant toxicity in maternal animals. Reduced sperm function was noted in male rats at high subcutaneous doses of tacrolimus.



6. Pharmaceutical Particulars



6.1 List Of Excipients



White soft paraffin



Liquid paraffin



Propylene carbonate



White beeswax



Hard paraffin



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



3 years



6.4 Special Precautions For Storage



Do not store above 25°C.



6.5 Nature And Contents Of Container



Laminate tube with an inner lining of low-density-polyethylene fitted with a white polypropylene screw cap.



Package sizes: 10 g, 30 g and 60 g. Not all pack sizes may be marketed.



6.6 Special Precautions For Disposal And Other Handling



No special requirements.



Any unused product or waste material should be disposed of in accordance with local requirements.



7. Marketing Authorisation Holder



Astellas Pharma Europe B.V.



Elisabethhof 19



2353 EW Leiderdorp



Netherlands



8. Marketing Authorisation Number(S)



EU/1/02/201/001



EU/1/02/201/002



EU/1/02/201/005



9. Date Of First Authorisation/Renewal Of The Authorisation



Date of first authorisation: 28/02/2002



Date of renewal: 20/11/2006



10. Date Of Revision Of The Text



23/06/2011



11. LEGAL CATEGORY


POM



Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.




Monday, 19 March 2012

Tylenol with Codeine #3



Generic Name: acetaminophen and codeine (a SEET a MIN o fen and KOE deen)

Brand Names: Capital with Codeine Suspension, Cocet, Cocet Plus, EZ III, Tylenol with Codeine #3, Tylenol with Codeine #4, Vopac


What is Tylenol with Codeine #3 (acetaminophen and codeine)?

Codeine is in a group of drugs called narcotic pain relievers. Acetaminophen is a less potent pain reliever that increases the effects of codeine.


The combination of acetaminophen and codeine is used to relieve moderate to severe pain.


Acetaminophen and codeine may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about Tylenol with Codeine #3 (acetaminophen and codeine)?


Tell your doctor if you have ever had alcoholic liver disease (cirrhosis) or if you drink more than 3 alcoholic beverages per day. You may not be able to take acetaminophen. Do not take more of this medication than is recommended. An overdose of acetaminophen can damage your liver or cause death. Avoid drinking alcohol. It may increase your risk of liver damage while taking acetaminophen. Ask a doctor or pharmacist before using any other cold, allergy, pain, or sleep medication. Acetaminophen (sometimes abbreviated as APAP) is contained in many combination medicines. Taking certain products together can cause you to get too much acetaminophen which can lead to a fatal overdose. Check the label to see if a medicine contains acetaminophen or APAP. Codeine may be habit-forming and should be used only by the person it was prescribed for. Keep the medication in a secure place where others cannot get to it. Acetaminophen and codeine may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.

What should I discuss with my healthcare provider before taking Tylenol with Codeine #3 (acetaminophen and codeine)?


Do not use this medication if you are allergic to acetaminophen (Tylenol) or codeine. Codeine may be habit-forming and should be used only by the person it was prescribed for. Never share acetaminophen and codeine with another person, especially someone with a history of drug abuse or addiction. Keep the medication in a place where others cannot get to it.

Tell your doctor if you drink more than three alcoholic beverages per day or if you have ever had alcoholic liver disease (cirrhosis). You may not be able to take medication that contains acetaminophen.


If you have any of these other conditions, you may need a dose adjustment or special tests:



  • asthma, COPD, sleep apnea, or other breathing disorders;



  • liver or kidney disease;


  • a history of head injury or brain tumor;




  • epilepsy or other seizure disorder;




  • low blood pressure;




  • a stomach or intestinal disorder;




  • underactive thyroid;




  • Addison's disease or other adrenal gland disorder;




  • enlarged prostate, urination problems;




  • curvature of the spine;




  • mental illness; or




  • a history of drug or alcohol addiction.




FDA pregnancy category C. It is not known whether this medication is harmful to an unborn baby, but it could cause breathing problems or addiction/withdrawal symptoms in a newborn. Tell your doctor if you are pregnant or plan to become pregnant while using this medication. Acetaminophen and codeine can pass into breast milk and may harm a nursing baby. The use of codeine by some nursing mothers may lead to life-threatening side effects in the baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I take Tylenol with Codeine #3 (acetaminophen and codeine)?


Take exactly as prescribed by your doctor. Do not take more of this medication than is recommended. An overdose of acetaminophen can damage your liver or cause death. Tell your doctor if the medicine seems to stop working as well in relieving your pain.

One acetaminophen and codeine tablet may contain up to 650 mg of acetaminophen. Know the amount of acetaminophen in the specific product you are taking.


Take this medicine with food or milk to ease stomach upset.

Measure liquid medicine with a special dose-measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.


Drink 6 to 8 full glasses of water daily to help prevent constipation while you are taking acetaminophen and codeine. Do not use a stool softener (laxative) without first asking your doctor. Do not stop using acetaminophen and codeine suddenly, or you could have unpleasant withdrawal symptoms. Ask your doctor how to avoid withdrawal symptoms when you stop using acetaminophen and codeine.

This medication can cause unusual results with certain urine tests. Tell any doctor who treats you that you are using acetaminophen and codeine.


If you need surgery, tell the surgeon ahead of time that you are using acetaminophen and codeine. You may need to stop using the medicine for a short time.


Store at room temperature away from moisture and heat. Keep track of the amount of medicine used from each new bottle. Codeine is a drug of abuse and you should be aware if anyone is using your medicine improperly or without a prescription.

What happens if I miss a dose?


Since this medication is taken as needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. An overdose of acetaminophen and codeine can be fatal.

Overdose symptoms may include extreme drowsiness, pinpoint pupils, cold and clammy skin, fainting, weak pulse, seizure (convulsions), coma, blue lips, shallow breathing, or no breathing.


The first signs of an acetaminophen overdose include loss of appetite, nausea, vomiting, stomach pain, sweating, and confusion or weakness. Later symptoms may include pain in your upper stomach, dark urine, and yellowing of your skin or the whites of your eyes.


What should I avoid while taking Tylenol with Codeine #3 (acetaminophen and codeine)?


This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Ask a doctor or pharmacist before using any other cold, allergy, pain, or sleep medication. Acetaminophen (sometimes abbreviated as APAP) is contained in many combination medicines. Taking certain products together can cause you to get too much acetaminophen which can lead to a fatal overdose. Check the label to see if a medicine contains acetaminophen or APAP. Avoid drinking alcohol. It may increase your risk of liver damage while taking acetaminophen.

Tylenol with Codeine #3 (acetaminophen and codeine) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have any of these serious side effects:

  • shallow breathing, slow heartbeat;




  • feeling light-headed, fainting;




  • confusion, unusual thoughts or behavior;




  • seizure (convulsions);




  • easy bruising or bleeding; or




  • nausea, stomach pain, loss of appetite, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).



Less serious side effects include:



  • feeling dizzy or drowsy;




  • mild nausea, vomiting, upset stomach, constipation;




  • headache;




  • blurred vision; or




  • dry mouth.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Tylenol with Codeine #3 (acetaminophen and codeine)?


Before taking acetaminophen and codeine, tell your doctor if you regularly use other medicines that make you sleepy (such as cold or allergy medicine, sedatives, other pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by codeine.

Also tell your doctor if you are using any of the following drugs:



  • glycopyrrolate (Robinul);




  • mepenzolate (Cantil);




  • atropine (Donnatal, and others), benztropine (Cogentin), dimenhydrinate (Dramamine), methscopolamine (Pamine), or scopolamine (Transderm-Scop);




  • bladder or urinary medications such as darifenacin (Enablex), flavoxate (Urispas), oxybutynin (Ditropan, Oxytrol), tolterodine (Detrol), or solifenacin (Vesicare);




  • a bronchodilator such as ipratroprium (Atrovent) or tiotropium (Spiriva); or




  • irritable bowel medications such as dicyclomine (Bentyl), hyoscyamine (Anaspaz, Cystospaz, Levsin, and others), or propantheline (Pro-Banthine).



This list is not complete and other drugs may interact with acetaminophen and codeine. Tell your doctor about all medications you use. This includes prescription, over the counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Tylenol with Codeine #3 resources


  • Tylenol with Codeine #3 Side Effects (in more detail)
  • Tylenol with Codeine #3 Use in Pregnancy & Breastfeeding
  • Drug Images
  • Tylenol with Codeine #3 Drug Interactions
  • Tylenol with Codeine #3 Support Group
  • 15 Reviews for Tylenol with Codeine #3 - Add your own review/rating


  • Cocet Plus Prescribing Information (FDA)

  • Tylenol with Codeine Prescribing Information (FDA)

  • Vopac Advanced Consumer (Micromedex) - Includes Dosage Information



Compare Tylenol with Codeine #3 with other medications


  • Cough
  • Osteoarthritis
  • Pain


Where can I get more information?


  • Your pharmacist can provide more information about acetaminophen and codeine.

See also: Tylenol with Codeine #3 side effects (in more detail)


Sunday, 18 March 2012

Ampicillin 500mg Vials for Injection





1. Name Of The Medicinal Product



Ampicillin 500mg Vials for Injection


2. Qualitative And Quantitative Composition



(Ampicillin Sodium BP for injection): Each vial contains 500mg ampicillin as Ampicillin Sodium EP.



3. Pharmaceutical Form



Vials containing sterile powder for injection.



4. Clinical Particulars



4.1 Therapeutic Indications



Ampicillin is a broad-spectrum penicillin, indicated for the treatment of a wide range of bacterial infections caused by ampicillin-sensitive organisms. Typical indications include: ear, nose and throat infections, bronchitis, pneumonia, urinary tract infections, gonorrhoea, gynaecological infections, septicaemia, peritonitis, endocarditis, meningitis, enteric fever, gastro-intestinal infections.



Extraperitoneal application of Ampicillin to wounds can be used to prevent infection following abdominal surgery.



Parenteral usage is indicated where oral dosage is inappropriate.



Routes of administration: Intramuscular, intravenous, intraperitoneal, intrapleural, intra-articular, extraperitoneal.



4.2 Posology And Method Of Administration



Usual adult dosage (including elderly patients):



Septicaemia, endocarditis, osteomyelitis: 500 mg four to six times a day IM or IV for one to six weeks.



Peritonitis, intra-abdominal sepsis: 500mg four times a day IM or IV.










Meningitis:




Adult dosage:




2 g six-hourly IV.




 




Children dosage:




150 mg/kg daily IV in divided doses.



Ampicillin may also be administered by other routes of conjunction with systemic therapy.



Intraperitoneal: 500 mg daily in up to 10 ml Water for Injections BP.



Intrapleural: 500 mg daily in 5-10 ml Water for Injections BP.



Intra-articular: 500 mg daily, in up to 5 ml Water for Injections BP or sterile 0.5% procaine hydrochloride solution.



Local use in abdominal surgery: 1 g sterile powder sprinkled into the wound extraperitoneally or into muscle layers to prevent wound infection post operatively.



Usual children's dosage (under 10 years)



Half adult routine dosage.



All recommended dosages are a guide only. In severe infections the above dosages may be increased.



Renal Impairment



In the presence of severe renal impairment (creatinine clearance <10ml/min) a reduction in dose or extension of dose interval should be considered. In cases of dialysis, an additional dose should be administered after the procedure.



Administration:



Intramuscular: Add 1.5 ml Water for Injections BP to 500mg vial contents.



Intravenous: Dissolve 500 mg in 10 ml Water for Injections BP. Administer by slow injection (three to four minutes). Ampicillin may also be added to infusion fluids or injected, suitably diluted, into the drip tube over a period of three to four minutes.



4.3 Contraindications



Ampicillin is a penicillin and should not be given to patients with a history of hypersensitivity to beta-lactam antibiotics (e.g. ampicillin, penicillins, cephalosporins) or excipients.



4.4 Special Warnings And Precautions For Use



Before initiating therapy with ampicillin, careful enquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics.



Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have been reported in patients receiving beta-lactam antibiotics. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of beta-lactam hypersensitivity.



Ampicillin should be avoided if infectious mononucleosis and/or acute or chronic leukaemia of lymphoid origin are suspected. The occurrence of a skin rash has been associated with these conditions following the administration of ampicillin.



Prolonged use may occasionally result in overgrowth of non-susceptible organisms.



Dosage should be adjusted in patients with renal impairment (see section 4.2).



Sodium content: One vial contains 33.7 mg of sodium. This sodium content should be included in the daily allowance of patients on sodium restricted diets.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



If Ampicillin is prescribed concurrently with an aminoglycoside, the antibiotics should not be mixed in the syringe, intravenous fluid container or giving set because loss of activity of the aminoglycoside can occur under these conditions.



Bacteriostatic drugs may interfere with the bactericidal action of ampicillin.



In common with other oral broad-spectrum antibiotics, ampicillin may reduce the efficacy of oral contraceptives and patients should be warned accordingly.



Probenecid decreases the renal tubular secretion of ampicillin. Concurrent use with ampicillin may result in increased and prolonged blood levels of ampicillin.



Concurrent administration of allopurinol during treatment with ampicillin can increase the likelihood of allergic skin reactions.



It is recommended that when testing for the presence of glucose in urine during ampicillin treatment, enzymatic glucose oxidase methods should be used. Due to the high urinary concentrations of ampicillin, false positive readings are common with chemical methods.



4.6 Pregnancy And Lactation



Pregnancy:



Animal studies with Ampicillin have shown no teratogenic effects. The product has been in extensive clinical use since 1961 and its use in human pregnancy has been well documented in clinical studies. When antibiotic therapy is required during pregnancy, Ampicillin may be considered appropriate.



Lactation:



During lactation, trace quantities of penicillins can be detected in breast milk. Adequate human and animal data on use of Ampicillin during lactation are not available.



4.7 Effects On Ability To Drive And Use Machines



Adverse effects on the ability to drive or operate machinery have not been observed.



4.8 Undesirable Effects



Hypersensitivity reactions:



If any hypersensitivity reaction occurs, the treatment should be discontinued.



Skin rash, pruritus and urticaria have been reported occasionally. The incidence is higher in patients suffering from infectious mononucleosis and acute or chronic leukaemia of lymphoid origin. Purpura has also been reported. Rarely, skin reactions such as erythema multiforme and Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported.



As with other antibiotics, anaphylaxis (see Item 4.4 – Warnings) has been reported rarely.



Renal effects:



Interstitial nephritis can occur rarely.



Gastrointestinal reactions:



Effects include nausea, vomiting and diarrhoea. Pseudomembraneous colitis and haemorrhagic colitis has been reported rarely.



Hepatic effects:



As with other beta-lactam antibiotics, hepatitis and cholestatic jaundice have been reported rarely. As with most other antibiotics, a moderate and transient increase in transaminases has been reported.



Haematological effects:



As with other beta-lactams, haematological effects including transient leucopenia, transient thrombocytopenia and haemolytic anaemia have been reported rarely.



Prolongation of bleeding time and prothrombin have also been reported rarely.



4.9 Overdose



Gastrointestinal effects such as nausea, vomiting and diarrhoea may be evident and should be treated symptomatically.



Ampicillin may be removed from circulation by haemodialysis.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Ampicillin is a broad spectrum penicillin, indicated for the treatment of a wide range of bacterial infections caused by ampicillin sensitive organisms.



5.2 Pharmacokinetic Properties



Ampicillin is excreted mainly in the bile and urine with a plasma half life of 1 – 2 hours.



5.3 Preclinical Safety Data



No further information of relevance.



6. Pharmaceutical Particulars



6.1 List Of Excipients



None



6.2 Incompatibilities



Ampicillin should not be mixed with blood products or other proteinaceous fluids (e.g. protein hydrolysates) or with intravenous lipid emulsions.



6.3 Shelf Life



36 months



6.4 Special Precautions For Storage



Ampicillin should not be stored above 25°C. Ampicillin Solutions for injection should be stored at 2-8°C in a refrigerator and used within 24 hours.



6.5 Nature And Contents Of Container



Clear glass vial (Ph.Eur Type 1) fitted with a butyl rubber plug and an aluminium seal – 10.



6.6 Special Precautions For Disposal And Other Handling



Ampicillin vials are not suitable for multidose use. Any residual Ampicillin solution should be discarded.



Administrative Data


7. Marketing Authorisation Holder



Essential Generics,



7, Egham Business Village,



Crabtree Road,



Egham,



Surrey,



TW20 8RB



8. Marketing Authorisation Number(S)



PL 17736/0070



9. Date Of First Authorisation/Renewal Of The Authorisation



25 February 2005



10. Date Of Revision Of The Text



21st March 2005



11 LEGAL STATUS


POM




Saturday, 17 March 2012

Gaviscon Peppermint Flavour Tablets





1. Name Of The Medicinal Product



Gaviscon Peppermint Flavour Tablets.


2. Qualitative And Quantitative Composition



Each tablet contains sodium alginate 250 mg, sodium hydrogen carbonate 133.5 mg and calcium carbonate 80 mg.



Excipients: Aspartame (E951) 3.75 mg per tablet.



For excipients, see Section 6.1.



3. Pharmaceutical Form



Chewable tablet.



An off-white to cream, slightly mottled tablet.



4. Clinical Particulars



4.1 Therapeutic Indications



Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion (related to reflux), for example, following meals or during pregnancy or in patients with symptoms related to reflux oesophagitis.



4.2 Posology And Method Of Administration



For oral use, after being thoroughly chewed.



Adults and children 12 years and over: Two to four tablets after meals and at bedtime.



Elderly: No dose modifications necessary for this age group.



4.3 Contraindications



This medicinal product is contraindicated in patients with known or suspected hypersensitivity to the active substances or to any of the excipients.



4.4 Special Warnings And Precautions For Use



The sodium content of a four-tablet dose is 246 mg (10.6 mmol). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment.



Each four-tablet dose contains 320 mg (3.2 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.



Due to its aspartame content this medicinal product should not be given to patients with phenylketonuria.



There is a possibility of reduced efficacy in patients with very low levels of gastric acid.



If symptoms do not improve after seven days, the clinical situation should be reviewed.



Treatment of children younger than 12 years of age is not generally recommended, except on medical advice.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Due to the presence of calcium carbonate which acts as an antacid, a time-interval of 2 hours should be considered between Gaviscon intake and the administration of other medicinal products, especially H2-antihistaminics, tetracyclines, digoxine, fluoroquinolone, iron salt, ketoconazole, neuroleptics, thyroxine, penicilamine, beta-blockers (atenolol, metoprolol, propanolol), glucocorticoid, chloroquine and diphosphonates.



4.6 Pregnancy And Lactation



Open controlled studies in 281 pregnant women did not demonstrate any significant adverse effects of Gaviscon on the course of pregnancy or on the health of the foetus/new-born child. Based on this and previous experience the medicinal product may be used during pregnancy and lactation. Nevertheless, taking into account the presence of calcium carbonate (see Section 5.3) it is recommended to limit the treatment duration as much as possible.



4.7 Effects On Ability To Drive And Use Machines



Not relevant.



4.8 Undesirable Effects



Very rarely (=1/10,000) patients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic and anaphylactoid reactions.



4.9 Overdose



In the event of overdose symptomatic treatment should be given. The patient may notice abdominal distension.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) ATC code: A02BX.



On ingestion the medicinal product reacts rapidly with gastric acid to form a raft of alginic acid gel having a near neutral pH and which floats on the stomach contents effectively impeding gastro-oesophageal reflux. In severe cases the raft itself may be refluxed into the oesophagus, in preference to the stomach contents, and exert a demulcent effect.



5.2 Pharmacokinetic Properties



The mechanism of action of the medicinal product is physical and does not depend on absorption into the systemic circulation.



5.3 Preclinical Safety Data



There is limited evidence in some reports in animals of delay in calcification of foetal skeleton/bone abnormalities relating to calcium carbonate.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Peppermint flavour



Macrogol 20,000



Mannitol (E421)



Copovidone



Aspartame (E951)



Acesulfame potassium (E950)



Magnesium stearate



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



2 years.



6.4 Special Precautions For Storage



Do not store above 30°C.



6.5 Nature And Contents Of Container



Unprinted, glass-clear, thermoformable laminate of uPVC/PE/PVdC with aluminium foil lidding blisters packed into cartons.



Blister pack containing 4, 6 or 8 individually sealed tablets.



Larger packs (16, 24, 32, 48 and 64) will be made up of multiples of the above units and packed into cartons.



Pack sizes 4, 6, 8, 16, 24, 32, 48 or 64 tablets



Polypropylene container containing 8, 12, 16, 18, 20, 22 or 24 tablets.



Multiple packs (2 x 16, 2 x 18, 2 x 20, 2 x 22 or 2 x 24) will be packed into cartons.



Pack sizes 8, 12, 16, 18, 20, 22, 24, 2 x 16, 2 x 18, 2 x 20, 2 x 22 or 2 x 24 tablets.



Not all pack sizes may be marketed.



6.6 Special Precautions For Disposal And Other Handling



No special requirements.



7. Marketing Authorisation Holder



Reckitt Benckiser Healthcare (UK) Limited,



Dansom Lane,



Hull,



HU8 7DS,



United Kingdom.



8. Marketing Authorisation Number(S)



PL 00063/0627



9. Date Of First Authorisation/Renewal Of The Authorisation



10/08/2010



10. Date Of Revision Of The Text



10/08/2010